Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies
Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain
These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain.
DELRAY BEACH, FL / ACCESS Newswire / June 15, 2025 / Adolore BioTherapeutics ('Adolore' or the 'Company'), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, 'Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1,' in the peer-reviewed journal, Molecular Therapy.
Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA.
Dr. Levitt, commented, 'Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102.'
The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026.
1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), https://doi.org/10.1016/j.ymthe.2025.05.02
About Carbonic Anhydrase-8 (CA8*) Gene Therapy
CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss.
About Adolore BioTherapeutics, Inc.
Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss.
Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss.
For more information, visit adolore.com.
Forward-Looking Statements
To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project,' 'will,' 'should,' 'may,' 'plan,' 'intend,' 'assume' and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements.
Investor Relations Contact
Paul Barone (215)622-4542
[email protected]
SOURCE: Adolore Biotherapeutics, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
DASH4D Diet for BP Control in T2D: Less Salt, Better Results
In adults with type 2 diabetes (T2D) on multiple antihypertensive medications, a modified Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) diet combined with reduced sodium intake led to a clinically relevant reduction in systolic blood pressure (BP), with the benefits primarily attributed to sodium reduction. METHODOLOGY: Although the original DASH diet — rich in fruits, vegetables, and low-fat dairy products and low in saturated fat and cholesterol — is recommended with sodium reduction for managing hypertension in patients with T2D, evidence of its effectiveness in this population remains limited. Researchers conducted a single-site study in Maryland to assess the efficacy of the DASH4D diet, featuring lower carbohydrates, higher unsaturated fats, and lower potassium than the original DASH diet, together with reduced dietary sodium for BP management in T2D. They included 102 adults with T2D (mean age, 66 years; 66% women) between June 2021 and December 2023; the patients had a mean baseline BP of 135/75 mm Hg; 66% of them used at least two antihypertensive medicines, and 55% used two or more glucose-lowering medicines. Participants were randomly assigned to be provided with four diets in sequence, each for 5 weeks: The DASH4D diet with lower sodium, DASH4D diet with higher sodium, typical US diet with lower sodium, and typical US diet with higher sodium; in a 2000-kcal menu, the lower and higher sodium levels were set at 1500 mg/d and 3700 mg/d, respectively. The primary outcome was end-of-period systolic BP, measured on 5 separate days during the last 2 weeks of each feeding period. TAKEAWAY: Compared with patients on the typical US diet with higher sodium, those who received the DASH4D diet with lower sodium showed an average systolic BP reduction of 4.6 mm Hg (95% CI, -7.2 to -2.0) and an average diastolic BP reduction of 2.3 mm Hg (95% CI, -3.7 to -0.9) after 5 weeks. Among patients on the DASH4D diet, systolic BP was reduced by 4.8 mm Hg (95% CI, -7.4 to -2.2) in those with lower vs higher dietary sodium. Most reductions in BP occurred during the first 3 weeks of each diet period. Patients completely adhered to the recommended diet for 96% of the study days. The frequency of adverse events was low. IN PRACTICE: '[The findings] provide evidence of the efficacy of BP lowering through dietary change in people with T2D, including those treated with multiple antihypertensive and glucose-lowering medications,' the authors of the study wrote. 'High adherence to the DASH4D lower sodium diet suggests that the diet is acceptable.' SOURCE: This study was led by Scott J. Pilla, MD, MHS, Johns Hopkins University School of Medicine in Baltimore. It was published online on June 9, 2025, in JAMA Internal Medicine . LIMITATIONS: This study was not powered sufficiently to detect individual effects of the DASH4D diet and sodium reduction. As a single-center study, the study population lacked diversity. Participant feeding was disrupted at multiple points owing to the COVID-19 pandemic. DISCLOSURES: This study received funding from the Sheikh Khalifa Stroke Institute at Johns Hopkins University School of Medicine, grants from National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute grant, and the National Center for Advancing Translational Science Awards Program. Several authors reported receiving grants from sources including the funding agency and National Institutes of Health. Some authors reported serving on the scientific advisory board or receiving personal fees outside the submitted work.
Associated Press
an hour ago
- Associated Press
Pager Health (SM) Launches Industry's First End-to-End Member Navigation Platform
Pager Health Navigator redefines the member experience by connecting provider, clinical, benefits, and program navigation in one seamless, AI-powered solution NEW YORK, June 16, 2025 /PRNewswire/ -- Pager Health, a connected health platform company serving more than 26 million members in the United States and Latin America, today announced the launch of Pager Health Navigator, a seamless, scalable, AI-powered care navigation system that radically transforms the health plan member experience. Pager Health Navigator is the first navigation solution to integrate four previously disconnected member services—provider, clinical, benefits, and program navigation—into one connected platform available through a single interface. By empowering members to steer their care with confidence, unmatched speed and convenience, Navigator seeks to elevate consumers' perception of health plans, establishing them as a trusted partner and central access point for their health journey. 'With the launch of Pager Health Navigator, the days of siloed and fragmented healthcare experiences that confuse members, delay care, and drive up costs are over,' said Walter Jin, Chairman and CEO of Pager Health. 'Navigator is more than an innovation; it's the arrival of a new standard in connected care. It unifies clinical, provider, solution, and benefits navigation to empower member engagement, replacing confusion with clarity and transforming a maze of disconnected touchpoints into a connected healthcare experience. Health plans can now finally deliver the seamless, personalized experience their members expect when using any other digital connection, while improving engagement, streamlining support, redirecting care to appropriate settings, and ultimately achieving meaningful ROI.' Four Powerful Navigation Tools, One Seamless Experience Pager Health Navigator's four core services use AI-powered features and other advanced capabilities to streamline care access, personalize member experiences, and reduce friction across the healthcare journey. In addition to unifying member navigation, Navigator leverages AI-powered personalized guidance throughout the entire member experience, from triage and benefits clarification to FAQs and next-best actions, with nurse-led support always available. Proactive outreach includes automated campaigns, targeted messages, and timely reminders for wellness visits and health assessments. Omnichannel member engagement across all major touchpoints, including SMS, app, portal, phone, secure chat, WhatsApp, and email, maximizes reach and responsiveness. Purpose-Built to Work Within Health Plans Specifically engineered to integrate with a health plan's existing technology stack and service operations, Navigator delivers a white-labeled experience that gives full credit to the health plan for facilitating the member experience. 'AI is rewriting the rules on how people connect with products and services, and healthcare is not immune to this revolution,' Jin said. 'It is now a market imperative for health plans to embrace AI innovation in member engagement and care coordination or risk irrelevance. Pager Health Navigator presents a pivotal opportunity for health plans to lead this transformation toward truly member-centered care.' With Navigator, Pager Health is advancing its mission to transform healthcare through smarter, more connected member experiences. This launch reinforces Pager's commitment to helping health plans generate seamless navigation, reduce costs, improve satisfaction, and deliver measurable value. For more information about Pager Health, please visit About Pager Health Pager Health is a connected health platform company that enables healthcare enterprises to deliver high-engagement, intelligent health experiences across wellness, care navigation, and care management engagement. Through integrated technology, AI, and concierge services, our platform helps patients and members get the right care at the right time in the right place and stay healthy. By reducing system friction and fragmentation, powering engagement, and orchestrating the enterprise, Pager Health drives better outcomes at scale. We partner with leading payers, providers, and employers, representing more than 26 million individuals across the United States and Latin America. Media Contact Pager Health Christopher Gale [email protected] View original content: SOURCE Pager Health
Associated Press
an hour ago
- Associated Press
Dr. Ashley Capps Unveils Premium Autoimmune Rebalance System: A Groundbreaking Approach to Autoimmune Recovery Through Trauma-Informed Healing
Dr. Ashley Capps announces the launch of her Autoimmune Rebalance System, offering a premium, trauma-informed healing approach for women to address autoimmune symptoms at their root causes. United States, June 16, 2025 -- Dr. Ashley Capps Introduces a Revolutionary Autoimmune Recovery System Focused on Trauma and Stress In an unconventional move that is redefining autoimmune disease recovery, Dr. Ashley Capps, a behavioral health doctor and licensed mental health therapist, has launched the Autoimmune Rebalance System. This premium, trauma-informed program is designed specifically to help women tackle the root causes of autoimmune diseases by focusing on the often-overlooked contributors of chronic stress, unresolved trauma, and nervous system dysregulation. Dr. Capps' approach challenges the traditional medical model, which often isolates the physical and mental aspects of health. By incorporating modern psychoneuroimmunology research, Dr. Capps provides a comprehensive, holistic framework for autoimmune recovery. This innovative program emphasizes the mind-body connection as a central pillar of healing, offering a more sustainable and integrated solution for those suffering from autoimmune conditions. The Trauma-Informed Approach to Autoimmune Recovery Unlike conventional programs that primarily focus on symptom management through diet, medications, or supplements, Dr. Capps' Autoimmune Rebalance System integrates trauma recovery at its core. By addressing the mental, emotional, and neurological influences on immune system function, Dr. Capps offers a comprehensive healing process that goes far beyond symptom suppression. 'Chronic stress and unresolved trauma have been shown to trigger immune dysfunction, and for many women, this often goes unaddressed in traditional medical care,' says Dr. Capps. 'We need to approach autoimmune disease recovery with a full understanding of how trauma impacts the body. It's not enough to simply treat the symptoms—we need to focus on healing the underlying emotional and psychological triggers that fuel autoimmune flare-ups.' The Autoimmune Rebalance System provides participants with the tools to regulate their nervous system, heal from past trauma, and manage the chronic stress that often leads to autoimmune dysfunction. This integrated approach empowers individuals to break free from the cycle of symptom management and instead focus on lasting recovery. How the Autoimmune Rebalance System Works: A Comprehensive and Compassionate Framework The Autoimmune Rebalance System is grounded in the principles of psychoneuroimmunology, which studies the relationship between the nervous system, immune system, and endocrine system. This premium program combines cutting-edge science with compassionate behavioral health practices to rewire how women relate to their bodies, health, and healing processes. Dr. Capps has spent over a decade refining this trauma-informed approach, and it is tailored specifically to address the unique challenges women face. Medical gaslighting, emotional labor, and identity shifts are common issues for women navigating autoimmune disease, and Dr. Capps has integrated these realities into the system's design. Rather than encouraging individuals to 'push through' their symptoms, Dr. Capps' program fosters a deeper connection to the body's natural healing mechanisms, focusing on nervous system regulation, emotional resilience, and real-time integration of recovery practices into daily life. The result is a personalized approach that prioritizes sustainable healing through compassionate, non-judgmental care. A New Standard for Women's Autoimmune Recovery The Autoimmune Rebalance System stands apart by offering a level of personalization and flexibility not often found in other programs. While many traditional systems rely on rigid regimens, Dr. Capps' program emphasizes flexible frameworks and compassionate consistency. The focus is on progress and healing, not perfection. Participants are encouraged to adapt to their own unique needs and experiences—whether navigating energy shifts, managing flare-ups, or addressing emotional waves—while building sustainable recovery practices. The system does not prescribe a one-size-fits-all solution, but rather empowers women to listen to their bodies and engage in a healing process that fits their individual circumstances. This tailored approach, grounded in a deep understanding of both the clinical and emotional aspects of autoimmune disease, positions Dr. Capps' Autoimmune Rebalance System as a premier resource for women seeking to take control of their health and well-being. A Personal Journey to Empowerment and Healing Dr. Ashley Capps is not only a recognized expert in the field of autoimmune recovery but also a passionate advocate for trauma-informed care. Her personal commitment to this work is rooted in a deep understanding of the complex intersection between trauma, stress, and autoimmune disease. Having worked with hundreds of women in clinical settings, Dr. Capps has seen firsthand how untreated emotional and psychological trauma can exacerbate autoimmune conditions. Her ability to blend clinical rigor with an intuitive, compassionate approach has made her a sought-after speaker and educator in the fields of women's health, chronic illness recovery, and trauma. Her unique qualifications allow her to guide women through a healing process that combines the latest science with practical, real-life tools. As Dr. Capps continues to expand the reach of her Autoimmune Rebalance System, she remains dedicated to reshaping the conversation about autoimmune disease. She firmly believes that true healing comes from addressing both the mind and body, and this system represents her commitment to helping women reclaim their health through holistic, trauma-informed care. About Dr. Ashley Capps and the Autoimmune Rebalance System Dr. Ashley Capps is a behavioral health doctor, licensed mental health therapist, and the founder of the Autoimmune Rebalance System. She has over a decade of clinical experience in trauma recovery, psychoneuroimmunology, and integrative behavioral health. Dr. Capps' innovative program blends cutting-edge research with compassionate care to help women heal from autoimmune diseases by addressing the root causes of chronic stress and trauma. Her system has been designed to provide a holistic and sustainable recovery experience, empowering women to take control of their health through personalized, trauma-informed healing practices. Media Contact: Dr. Ashley Capps Phone: 850-527-5488 Email: [email protected] Contact Info: Name: Dr. Ashley Capps Email: Send Email Organization: The Autoimmune Rebalance System Website: Release ID: 89162375 In case of identifying any problems, concerns, or inaccuracies in the content shared in this press release, or if a press release needs to be taken down, we urge you to notify us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your concerns and take swift action within 8 hours to rectify any issues identified or assist with the removal process. We are committed to delivering high-quality content and ensuring accuracy for our valued readers.
